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Background: The individual contribution of HYAL1 and -hexosaminidase to glycosaminoglycan (GAG) degradation is
not fully understood.
Results:Mice deficient in both of these enzymes exhibit global accumulation of hyaluronan and related GAGs.
Conclusion: A functional redundancy exists between HYAL1 and -hexosaminidase.
Significance: Investigating the contribution of individual hyaluronidases and exoglycosidases is critical to understanding the
overall pathways of GAG catabolism.
Hyaluronan (HA), amember of the glycosaminoglycan (GAG)
family, is a critical component of the extracellular matrix. A
model for HA degradation that invokes the activity of both hya-
luronidases and exoglycosidases has been advanced. However,
no in vivo studies have been done to determine the extent to
which these enzymes contribute to HA breakdown. Herein, we
used mouse models to investigate the contributions of the
endoglycosidase HYAL1 and the exoglycosidase -hexosamini-
dase to the lysosomal degradation of HA. We employed histo-
chemistry and fluorophore-assisted carbohydrate electrophore-
sis to determine the degree of HA accumulation in mice
deficient in one or both enzyme activities. Global HA accumu-
lation was present in mice deficient in both enzymes, with the
highest levels found in the lymph node and liver. Chondroitin, a
GAG similar in structure to HA, also broadly accumulated in
mice deficient in both enzymes. Accumulation of chondroitin
sulfate derivatives was detected in mice deficient in both
enzymes, as well as in -hexosaminidase-deficient mice, indi-
cating that both enzymes play a significant role in chondroitin
sulfate breakdown. Extensive accumulation of HA and chon-
droitinwhen both enzymes are lackingwas not observed inmice
deficient in only one of these enzymes, suggesting that HYAL1
and -hexosaminidase are functionally redundant in HA and
chondroitin breakdown. Furthermore, accumulation of sulfated
chondroitin in tissues provides in vivo evidence that both
HYAL1 and-hexosaminidase cleave chondroitin sulfate, but it
is a preferred substrate for -hexosaminidase. These studies
provide in vivo evidence to support and extend existing knowl-
edge of GAG breakdown.
Hyaluronan (HA)3 is a large polysaccharide made up of
repeating units of GlcUA and GlcNAc. It is a member of the
glycosaminoglycan (GAG) family that consists of several
uronic-acid containing polymers that are defined by their
unique repeating disaccharide units, including HA, chondroi-
tin, and sulfated derivatives of chondroitin (1). HA is abundant
in the extracellular matrix of vertebrate tissues, where it pro-
vides structural integrity to tissues and cells. In addition, HA
has been shown to have functional roles in inflammation (2),
ovulation (3), and other processes. Moreover, HA is used
broadly in medical devices, medical treatments, and cosmetic
applications (4). Despite the wide distribution of HA and its
diverse roles in tissues, the pathways of its catabolism are still
not completely understood.
A model for HA degradation was initially proposed by Has-
call et al. (5) and further advanced by Stern (6, 7). This model
proposes that the degradation begins with cleavage of high to
low molecular weight HA by an extracellular hyaluronidase
enzyme, HYAL2. HA fragments are then internalized through
interactions with a cell surface receptor such as CD44 (8, 9),
LYVE-1 (lymphatic vessel endothelial HA receptor-1) (10), or
HARE (HA receptor for endocytosis) (11). Once internalized,
the endosome matures to a lysosome, where other hyaluroni-
dases break HA down to generate short oligosaccharides that
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are putative substrates for the lysosomal exoglycosidases-glu-
curonidase and-hexosaminidase (6). Recently, usingC57BL/6
mice, it was shown that someHAdegradation can occur locally,
but most is degraded in the lymphatics, and low levels are also
disposed of in the liver (12).
The lysosomal degradation of HA is supported by studies
showing that inhibitors of lysosomal function disrupt HA deg-
radation (9, 13). However, within the lysosome, the individual
contributions of hyaluronidases and exoglycosidases to the
breakdown of HA are still to be defined. Lowmolecular weight
HA has been suggested as a potential substrate for the endogly-
cosidases HYAL1 and HYAL3 (6, 14). However, HYAL1 is
expressed highly in a broad range of tissues, whereasHYAL3 is
expressed at extremely low levels (15), suggesting that HYAL1
may play a larger role in the degradation of HA. Furthermore,
human mutations in hyaluronidase-coding genes have been
found only in HYAL1 and cause mucopolysaccharidosis IX
(OMIM 601492) (15, 16). Physical characteristics of mucopoly-
saccharidosis IX are limited primarily to cartilaginous tissues
and are considered relatively mild compared with other muco-
polysaccharidoses (15, 16).
Given the rapid turnover of HA in some tissues (4), substan-
tial accumulation of HA was predicted in the absence of an
enzyme required for its degradation. However, HA accumula-
tion in multiple tissues was not identified in transgenic mice
deficient in any one hyaluronidase (17–19). This lack of HA
accumulation and the mild phenotype observed in HYAL1-de-
ficient patients could potentially be explained by a functional
redundancy between the highly expressed HYAL1 and another
lysosomal HA-degrading enzyme.
One potential compensating enzyme, -hexosaminidase
(N-acetyl--D-glucosaminidase), is a lysosomal exoglycosidase
that has been shown to cleave HA in vitro (1). The enzyme is
coded for by HEXA and HEXB, which produce the -subunit
and -subunit, respectively. Isoforms of the enzyme consist of
an -subunit homodimer (-hexosaminidase S), a -subunit
homodimer (-hexosaminidase B), and a heterodimer of both
subunits (-hexosaminidase A) (20). In humans, mutations of
HEXA and HEXB are familiarly associated with the lysosomal
storage disorders Tay-Sachs disease (OMIM 272800) and
Sandhoff disease (OMIM 268800), respectively. These disor-
ders, both categorized as GM2 gangliosidoses, are character-
ized by extensive accumulation of gangliosides that cannot be
degraded in the absence of -hexosaminidase A (21). Interest-
ingly, however,mice deficient in all-hexosaminidase isoforms
(Hexa/ Hexb/) also demonstrate a mucopolysaccharido-
sis-like phenotype, which includes accumulation of both GAGs
and gangliosides in multiple tissues (22, 23). The identity of
these GAGs was not fully investigated and could therefore
includeHA and others.Monosaccharide analysis completed on
urine excreted from mice deficient in all isoforms of -hexo-
saminidase showed extensive accumulation of two monosac-
charides common to the structure of dermatan sulfate (22).
However, it has previously been shown that excretion of HA
through the urinary system accounts for only 1% of normal HA
turnover (24). Therefore, accumulation of HA in -hexo-
saminidase-deficient mice may have been missed, as the iden-
tities of individual GAGs were not assayed in tissues.
In this study, we focused on the characterization of GAGs in
a triple knock-out (TKO)mousemodel deficient inHYAL1 and
all isoforms of -hexosaminidase. GAGs were also assayed in
tissues frommice with deficiencies in eitherHYAL1 or-hexo-
saminidase activity. These mouse models allowed us to explore
the possibility of functional redundancies within the proposed
model of HA breakdown. In addition, wewere able to assess the
contributions of these enzymes in the catabolism of other
members of the GAG family. TKO mice displayed global HA
accumulation, with the highest levels of HA in the liver and
lymph node; this extensive accumulation of HA was not
observed in mice deficient in only one of these enzyme activi-
ties. These results serve to further define the overall pathway of
HA degradation, the major tissues involved, and the functional
redundancies that exist in HA breakdown. Furthermore, the
functional redundancy between-hexosaminidase andHYAL1
may explain the mild phenotype observed in patients with a
HYAL1 deficiency (15, 16, 25) and potentially create treatment
options for these patients.
EXPERIMENTAL PROCEDURES
Generation of Experimental Animals—C57BL/6;C129 mice
heterozygous for Hexa and Hexb gene disruptions (Hexa/
Hexb/) were characterized previously (26) and crossed with
C57BL/6 mice heterozygous for a deletion in the Hyal1 gene
(Hyal1/) that were purchased from MMRRC (MMRRC:
000086-UCD, Davis, CA) and have been described in detail
(19). Mice heterozygous at all three loci (Hexa/ Hexb/
Hyal1/) were bred to generate TKO mice (Hexa/
Hexb/ Hyal1/), and double knock-out (DKO) sex-
matched littermates (Hexa/ Hexb/ Hyal1/) served as
controls. Wild-type mice (Hexa/ Hexb/ Hyal1/) were
also generated from the above crosses. Mice with the correct
genotypes were identified by PCR amplification of DNA from
ear punches. The wild-type and disrupted Hexa and Hexb
alleles were amplified as described previously (26), except the
denaturing and annealing steps were programmed for 1 min.
The wild-type Hyal1 allele was amplified using established
methods (19). However, because the disrupted alleles for Hexa
andHexb also contained a neomycin cassette, different primers
and conditions were required to detect the deletedHyal1 allele.
WPG 617 (5-ATCGCCTTCTATCGCCTT-3) and WPG 619
(5-GAGACATGCCTTGAACTCTGCCTCC-3) were used to
amplify a 450-bp band using the same PCR conditions specified
for the wild-type and disrupted Hexa and Hexb alleles (26).
TKO mice displayed severe neurological deterioration
requiring euthanasia at 4 weeks of age. Tissues from TKO
mice, sex-matched DKO control littermates, and sex- and age-
matched wild-type mice were collected, frozen at 80 °C for
biochemical studies, or fixed in 10% buffered formalin (Fisher)
containing 0.5% hexadecylpyridinium chloride (Sigma-Al-
drich) for histological studies. Tissues fixed for histological
studies were embedded in paraffin and sectioned at 5 m. All
procedures and care of the animals were in compliancewith the
CanadianCouncil onAnimal Care and approved by theAnimal
Protocol Management and Review Committee at the Univer-
sity of Manitoba.
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Histological Studies—H&E staining was completed to assess
overall tissue morphology as described previously with some
modifications (27). Mayer’s hematoxylin was applied for 3 min,
followed by a 6-min wash with running tap water and eosin
incubation for 40 s. Alcian blue staining (pH 2.5) of GAGs in
tissue sections was carried out as described (28), except the
slides were counterstained with Nuclear Fast Red (ScyTek Lab-
oratories) for 2.5 min. HA was localized in tissue sections by
using the biotinylated HA-binding protein (HABP; Calbi-
ochem) at 6.67 g/ml as described (19), omitting the trypsin
treatment step. Colorimetric development of positive staining
was done with diaminobenzidine without nickel to produce a
visible brown color. Slides were counterstained with hematox-
ylin for 2min, followed by a 5-minwashwith running tapwater.
Slides were then dehydrated, mounted, and visualized using
bright-field microscopy.
Fluorophore-assisted Carbohydrate Electrophoresis—HA
and other GAG levels in dried mouse tissues were quantified
using fluorophore-assisted carbohydrate electrophoresis
(FACE) as described previously (29) with the following adjust-
ments. Following the deactivation of proteinase K (Sigma) by
boiling, samples were extractedwith acetone (3 parts acetone/1
part supernatant) and stored at 20 °C for 2 h. After the first
ethanol precipitation, precipitates were pelleted, reconstituted
with ultrapurewater, and divided into three aliquots. Individual
aliquots were treated with 5 milliunits of hyaluronidase SD
(Seikagaku) or chondroitinase ABC (Sigma-Aldrich) in 200mM
ammonium acetate buffer using the pH recommended by the
supplier. The third aliquot received no enzyme treatment and
served as a negative control. Samples were incubated overnight
at 37 °C. The resulting disaccharides were then isolated and
labeled as described (29). Labeled disaccharide units were sep-
arated on a 20% acrylamide gel using previously described con-
ditions (30). Fluorescence signals were imaged using a Fluor-S
MultiImager (Bio-Rad) and quantified by comparison with
fluorescently labeled disaccharide standards (Seikagaku) using
Quantity One software. Unpaired Student’s t tests were used to
test for statistical significance, and p values0.05 were consid-
ered significant.
RESULTS
Phenotype of Hexa/Hexb/Hyal1/ (TKO)Mice—The
phenotype of the TKO mice was found to be similar to that
described previously for Hexa/ Hexb/ (DKO) mice (22,
23) but more severe. A significant difference was observed
between the life spans of the TKO andDKOmice (p 0.04). At
23 days, the TKO mice reached the predetermined humane
endpoint of inability to feed and/or reducedmobility compared
with an average of 33 days for the DKO mice. The TKO mice
were smaller than their DKO littermates, and leading up to the
humane end point, they displayed tremors, seizure-like epi-
sodes, and labored breathing. Both TKO mice and their DKO
littermates displayed a broad nose typical of mucopolysaccari-
doses in mouse models (17, 31, 32).
Tissue Morphology and Substrate Accumulation—Tissue
sections from 4-week-old TKO and DKO mice stained with
H&E showed pronounced cellular vacuolization compared
with wild-type tissues (Fig. 1A). The cellular vacuolization was
consistent with intracellular macromolecule accumulation.
However, there was no apparent difference in the overall vacu-
olization of TKO tissues compared with DKO tissues. Vacuol-
ization due to substrate accumulation was observed inmultiple
tissues and was typical of a lysosomal storage disorder.
Alcian blue staining of TKO and DKO tissue sections
resulted in an intense specific blue staining in both TKO and
DKO tissues, whereas wild-type tissues stained much weaker
(Fig. 1B). Furthermore, the staining in some of the TKO tis-
sues (liver, skin, and brain) was more intense that that in
DKO tissues, indicating an increased level of GAG accumu-
lation in these tissues. The greater accumulation of GAG in
the TKO mice suggests a redundancy between HYAL1 and
-hexosaminidase.
Localization and Accumulation of HA in Tissues—The fail-
ure to detectGAGaccumulation inHYAL1-deficientmice (19),
together with demonstrated GAG accumulation in DKO mice
(22), suggested that HAmay be one of the accumulating GAGs
in the DKO mice. Surprisingly, an elevation of HA was not
detected in DKO tissues compared with wild-type tissues after
employing histochemistry (Fig. 2). Therefore, we wanted to
assess HA accumulation in tissues from mice lacking both
HYAL1 and -hexosaminidase activities. Fig. 2 shows the dis-
tribution of HA in the liver, skin, brain, and lung detected using
HABP (brown straining). HA accumulationwas apparent in the
sinusoids of the liver (Fig. 2A), around the periphery of vacuo-
lated neural cells in the brain (Fig. 2G), and in themucosal folds
of the bronchiole (Fig. 2J) in the TKO mice. DKO tissue con-
trols (Fig. 2, B,H, andK) for the liver, brain, and lung lacked the
distinct staining patterns observed in the TKO mice. In skin
(Fig. 2, D and E), HA levels appeared to be similar in the TKO
mice and DKO controls. Negative controls showing the
remaining signal after digestion with hyaluronidase were com-
pleted on all tissues. Fig. 2 (M–O) shows representative nega-
tive controls for TKO, DKO, and wild-type lung tissue.
Identification and Quantification of GAGs by FACE—FACE
was performed to identify and quantify the levels of various
GAGs, including HA, in the tissues of TKO and DKO control
mice. GAGs were isolated from tissues and digested to their
unique disaccharide units for quantification. A representative
gel is shown in Fig. 3.
Given that the liver and lymph node are major turnover tis-
sues for displaced HA (33, 34), we wanted to quantify HA levels
in these tissues fromTKOmice using FACE (Fig. 4A). HA levels
were found to have reached an average of 78 ng/mg in the liver,
far higher than the average level of 0.8 ng/mg detected in DKO
controls (p  0.003, n  3). Extensive accumulation was also
seen in the lymph node, with levels reaching 48 ng/mg com-
pared with 4 ng/mg in DKO controls (p  0.02, n  3). Inter-
estingly, HA levels observed in TKO liver and lymph node were
3.6- and 2.2-fold higher, respectively, than those in TKO skin,
a tissue known to have a high concentration of HA. The GAG
accumulation in the TKOmice was not limited to HA, as chon-
droitin, a GAG very similar in structure to HA, was found to be
higher in the liver (p  0.001, n  3) and lymph node (p 
0.0005, n 3) in TKOmice compared with DKO controls (Fig.
4B). In addition to HA and chondroitin accumulation, TKO
liver samples displayed significant accumulation of some forms
Redundancy between Hyaluronidase 1 and-Hexosaminidase
MAY 11, 2012•VOLUME 287•NUMBER 20 JOURNAL OF BIOLOGICAL CHEMISTRY 16691
 by guest on A
pril 7, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
of sulfated chondroitin (Fig. 4C), including chondroitin 2-sul-
fate (p 0.005, n 3) and chondroitin type E (p 0.02, n 3).
Significant accumulation of HA in tissues that are not major
areas of its overall turnover was also identified. In TKO brain
(p 0.03, n 3) and lung (p 0.02, n 4), the concentration
of HA was 5 and 3 ng/mg, respectively, whereas DKO controls
displayedmuch lower levels in the brain (0.9 ng/mg) and lung (1
ng/mg) (Fig. 5A). Due to variation within the group, accumula-
tion of HA in TKO skin (p  0.06, n  5) was not found to be
statistically significant, although average levels (22 ng/mg)were
4.4-fold higher than in DKO controls (5 ng/mg; n 4). Sim-
ilar to tissues with high levels of HA turnover, chondroitin also
showed significant levels of accumulation in TKO skin, brain,
and lung samples (Fig. 5B). Interestingly, brain samples from
TKOmice displayed significant accumulation of sulfated chon-
droitin derivatives compared with DKO controls (Fig. 5C),
although levels of sulfated chondroitin in TKO lymph node,
skin, and lung were similar to DKO levels (data not shown).
Quantification of GAGs in Hyal1/ and DKO Mice Using
FACE—The identification of extensive HA accumulation in
TKO tissues using FACE (Figs. 4A and 5A) was unexpected
given the modest elevation in HA that was detected using the
HABP (Fig. 2). Because previous studies of Hyal1/-deficient
mice focused on totalGAG levels (19) and studies completed on
FIGURE 1. Analysis of tissue morphology and GAG distribution in TKO, DKO, and wild-type mice. A, H&E staining was completed to assess tissue
morphology. The liver is shown as a representative tissue at100magnification. Intracellular vacuolization was apparent in both TKO and DKO sections, but
not in WT liver. B, tissue sections were stained with Alcian blue, and the presence of GAGs was observed (blue staining) at63magnification. Compared with
WT and DKOmice, TKOmice displayedmore intense staining in the sinusoids of the liver (arrowhead), throughout the skin, and in the cytoplasm (arrowhead),
as well as around vacuolated neural cells in the brain (arrow). Similar intensities of staining were seen in lung sections from TKO and DKOmice.
Redundancy between Hyaluronidase 1 and-Hexosaminidase
16692 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 20•MAY 11, 2012
 by guest on A
pril 7, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
DKO mice used only monosaccharide analysis of urine (22) or
HABP (Fig. 2), we decided to use FACE to examine GAG levels
in tissues frommice with isolated deficiencies of either-hexo-
saminidase or HYAL1. We used mice with a C57BL/6;C129
background, whereas previous Hyal1/ studies were com-
pleted using C57BL/6 mice (19); therefore, where possible,
FACE was performed onHyal1/-deficient tissues from both
the C57BL/6 (previous studies) and C57BL/6;C129 (this study)
backgrounds.
These studies allowed us to verify that the increase in HA
seen in TKO tissues was a product of the loss of both HYAL1
and -hexosaminidase activities. Of the -hexosaminidase-de-
ficient tissues examined, only the livers (p  0.04, n  6) and
lymph nodes (p  0.02, n  4) of DKO mice demonstrated
significant HA accumulation compared with the livers (n 5)
and lymph nodes (n 4) of wild-type controls (Fig. 6A). These
levels were 41–608-fold lower than those seen in the livers
and lymph nodes of TKO mice (Fig. 4A).
In the analysis of Hyal1/ tissues from the C57BL/6;C129
background, no statistically significant elevation in HA was
found compared with wild-type controls (Fig. 6B). However, a
definite trendwas apparent, withHYAL1-deficient tissues con-
sistently showing higher levels of HA than observed in wild-
type controls but lower levels than observed in the TKO tissues
(Figs. 4 and 5). Significant HA accumulation was only seen in
the livers (p  0.006, n  4) of C57BL/6 Hyal1/ mice com-
pared with wild-type controls (Fig. 6C), and again, these levels
were 660-fold lower than those observed in the TKO mice
(Fig. 4A). Furthermore, this statistically significant elevation
in HA was in tissues isolated from 1-year-oldHyal1/mice
as part of a previous study (19). No tissues at early time
points were available from the C57BL/6 line, and it is possi-
FIGURE2.HA localization in tissuesofTKO,DKO,andWTmice.HAwasdetected in tissue sectionsof TKO,DKO, andWTmiceby stainingwithHABP, followed
by viewing at63magnification (A–O). Liver sections from TKOmice (A) displayed increased sinusoidal staining (arrowhead) comparedwith DKO controls (B)
andWT liver (C). The skin (D, E, and F) was positive for HA, but the intensities were similar to each other. Brain sections from TKOmice (G) showed HA staining
in theperiphery of vacuolatedneural cells (arrowheads), whichwas absent inDKOcontrols (H) andWTbrain (I). HAaccumulationwas apparent inmucosal folds
of the bronchiole (arrowheads) in TKO mice (J) compared with DKO controls (K) and WT lung (L). M–O served as negative controls, as the HA signal was not
present after treatment with hyaluronidase from Streptomyces hyalurolyticus.
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ble that the observed accumulation in the liver would not be
present at earlier time points. At the time of necropsy of the
C57BL/6Hyal1/mice, lymph nodes were isolated only for
histological studies and were therefore not available for
FACE studies.
Chondroitin did not accumulate in the DKOmice, C57BL/6;
C129 Hyal1/ mice, or C57BL/6 Hyal1/ mice compared
with wild-type controls (data not shown). Furthermore, in
those tissues tested, no sulfated chondroitin derivatives were
found to be accumulating in either background of Hyal1/
mice compared with wild-type controls (data not shown).
Interestingly, the DKO mice did show tissue-specific accumu-
lation of various derivatives of chondroitin sulfate, with accu-
mulation in the liver, lymph node, and lung (Fig. 7), but not in
the brain or skin (data not shown).
DISCUSSION
The important structural and functional roles of HAmake it
a critical component of the extracellular matrix. Study of the
degradation of this macromolecule within tissues has attracted
interest from the extracellular matrix field for several years (5,
6, 12, 14). However, despite the development of several mouse
models (17–19, 22, 23), the extent to which individual hyalu-
ronidases and exoglycosidases participate in HA turnover was
largely unknown. To gain further insight into the contribution
of individual hyaluronidases and exoglycosidases in this proc-
ess, we focused on two lysosomal enzymes proposed to be
involved in the breakdownofHAusingmultiplemousemodels.
We have demonstrated that both the endoglycosidase HYAL1
and the exoglycosidase -hexosaminidase are able to degrade
HA fragments and other GAGs in vivo.
Ubiquitous accumulation of HA was found in mice geneti-
cally modified to have a combined deficiency of both HYAL1
and -hexosaminidase activities. However, studies conducted
in mice deficient in solely HYAL1 or -hexosaminidase also
showed tissue-specific accumulation of HA, albeit at much
lower levels than seen with the combined deficiency. The HA
accumulation observed after the loss of both HYAL1 and
-hexosaminidase activities can thus be attributed to a func-
tional redundancy between the lysosomal hyaluronidase and
the exoglycosidases -hexosaminidase and -glucuronidase.
This redundancy may account for the relatively mild but still
debilitating phenotype seen in human HYAL1-deficient
patients (15, 16, 25), as -hexosaminidase and -glucuronidase
would still be functional and able to degrade HA. Given the
above redundancy, treatments that increase the amount of
-hexosaminidase and/or -glucuronidase to supplement HA
degradation in the joint could be useful in patients withHYAL1
deficiency.
Many studies have identified the lymph node and liver as
principal sites of HA uptake and turnover (12, 24, 33–35); our
results support these findings. Although TKO mice displayed
global tissue accumulation of HA, the liver and lymph node
showed much more extensive accumulation than the other tis-
sues tested. A prior study of tissue HA distribution showed that
the liver and lymph node normally have low levels of HA,
whereas a tissue such as the skin has high levels of HA (24).
Because the accumulated HA in the TKO liver and lymph node
exceeded the concentration of that in tissues with high HA
levels such as the skin, theHA is likely to have been transported
to these tissues.
HA turnover studies suggest that peripheral tissue HA is
brought to the lymph node, where it is degraded and recycled.
Residual HA that reaches the blood is then sequestered by the
liver anddegraded (24, 36). TKOmice, deficient in bothHYAL1
and -hexosaminidase, displayed the highest level of HA accu-
mulation in the liver, followed by the lymph node. However,
mice deficient only in -hexosaminidase displayed the greatest
HA accumulation in the lymph node, with only a small accu-
mulation in the liver. The former supports previous work sug-
gesting that peripheralHA is first brought through the lymph to
the lymph nodes, with a minor amount entering the blood-
stream to the liver. Consequently, the organ distribution of HA
accumulation in the TKO mice contradicts previous findings.
However, based on the immense accumulation of HA globally
in the TKO mice, the extensive amount of HA accumulated in
the liver may just be a result of the liver having a greater overall
HA storage capacity. Thus, with the lymphatic system at
threshold, the efficiency of HA removal from the lymph would
subsequently be hindered and allow more HA to be passed
through the efferent lymphatics to the bloodstream and accu-
mulate in the liver as a secondary site.
The broad HA accumulation observed in the TKO mice
affectedmany tissues, including the brain. TKOmice displayed
similar neurological deterioration as seen in the DKO controls,
but the symptoms appeared10 days earlier. We suggest that
the observed early deterioration is the result of neuronal toxic-
ity due to the accumulation ofmultiple GAGs, includingHA, as
this accumulation was not seen in brain samples from mice
deficient in either HYAL1 or -hexosaminidase. The accumu-
lation of other GAGs, primarily heparin sulfate, has previously
been hypothesized as the cause of the neuropathy associated
with several other mucopolysaccaridoses (38). Another possi-
bility for the decreased life span is that the extensive accumu-
FIGURE 3. FACE of various GAG disaccharides. GAG disaccharides in TKO
and DKO mouse tissue samples were analyzed using FACE. Tissue homoge-
nates were digestedwith hyaluronidase SD (Hyal) to produce HA disaccha-
rides (GlcUA-GlcNAc). Chondroitinase ABC (ABC) was used to generate
disaccharides of chondroitin (0S; GlcUA-GalNAc) and its sulfated derivatives,
including type A (4S; GlcUA-GalNAc4S), type C (6S; GlcUA-GalNAc6S), chon-
droitin 2-sulfate (UA2S;GlcUA-GalNAc2S), typeE (SE; GlcUA-GalNAc4,6S), type
D (SD; GlcUA2S-GalNAc6S), and dermatan sulfate (SB; IdoA-GalNAc4S). A lad-
der of fluorescently labeleddisaccharideswas used todetermine theposition
of each disaccharide. To serve as a negative control, an aliquot of the tissue
homogenate was not digested (None).
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lation of GAGs reduced the efficacy of the lysosomal break-
down of other cellular material, resulting in cell toxicity.
Regardless of the cause of early deterioration, the accumulation
ofHAafter the loss of bothHYAL1 and-hexosaminidase indi-
cates that HYAL1 plays an important role in HA degradation in
the brain; thiswas surprising, asHYAL1was previously thought
to be weakly expressed in the brain (15). This finding suggests
that the supplemental relationship between HYAL1 and
-hexosaminidase is critical for the proper breakdown ofHA in
the brain.
FIGURE4.QuantificationofGAGs inhighHAturnover tissues.FACEwasused toquantifyHA (A), 0S (B), and sulfatedchondroitin (C) in TKOandDKO liver (n
3) and lymph node (n  3). A, the level of HA was found to be significantly higher in TKO liver (p  0.003) and lymph node (p  0.02) compared with DKO
controls. B, unlike DKO controls, TKO liver (p 0.001) and lymph node (p 0.0005) also significantly accumulated chondroitin. C, TKO liver samples also had
significantly higher levels of UA2S (p 0.005), and SE (p 0.02). 4S/6S (p 0.1) did not significantly accumulate in TKO liver samples. Average levels of GAGs
are shown in ng/mg of tissue with S.E. *, p 0.05; **, p 0.01; ***, p 0.001.
FIGURE 5.Quantification of GAG accumulation in other tissues. FACEwas used to quantify HA (A), 0S (B), and sulfated chondroitin (C) in the skin, brain, and
lung.A, HA levelswere significantly higher in TKObrain (p0.03,n3) and lung (p0.02,n4) than inDKOcontrols. AccumulationofHAwasnot statistically
significant in TKO skin samples (p 0.06, n 5). B, TKO skin (p 0.04, n 5), brain (p 0.0003, n 3), and lung (p 0.003, n 4) also had higher levels of
chondroitin compared with DKO controls. C, TKO brain samples had significantly higher levels of 4S/6S (p 0.01, n 3) and UA2S (p 0.006, n 4). SE levels
did not differ significantly between the TKO and DKO samples (p 0.09, n 4). Average levels of GAGs are shown in ng/mg of tissue with S.E. *, p 0.05; **,
p 0.01; ***, p 0.001.
FIGURE 6.Quantification of HA levels in DKO andHyal1/mice comparedwithWTmice.HA concentrationwas determined by FACE inmice deficient in
either -hexosaminidase (A) or HYAL1 (B and C). A, DKOmouse tissues with significant accumulation included the liver (p 0.04, n 6) and lymph node (p
0.02, n 4) compared with WT liver (n 5) and lymph node (n 4). B, C57BL/6;C129 Hyal1/mice (n 3) did not significantly accumulate HA in any of the
tissues tested; however, levels were consistently higher in HYAL1-deficient tissues than inWT tissues. C, C57BL/6Hyal1/mice displayed accumulation in the
liver (p 0.006, n 4). Average levels of GAGs are shown in ng/mg of tissue with S.E. *, p 0.05.
FIGURE 7.Quantificationof accumulating chondroitin sulfate derivatives inDKOmouse tissues. Levels of chondroitin sulfate derivativeswere quantified
inDKOmice using FACE. Tissueswith significant accumulation included the liver (A), lymphnode (B), and lung (C).A, TKO liver (n 5) significantly accumulated
4S/6S (p 0.01) and SE (p 0.02) compared withWT liver (n 4). UA2S levels were higher in DKOmice but not statistically significant (p 0.09, n 5). B, the
lymph node accumulated significant levels of 4S/6S (p 0.0003, n 5), SE (p 0.047, n 4), and SB (p 0.001, n 4). UA2S levels in the DKO lymph node
samples were higher than in WT samples; however, they were not statistically significant due to variation within the group (p  0.1, n  3). C, the lung
accumulated significant levels of 4S/6S (p 0.005, n 5), UA2S (p 0.003, n 5), SE (p 0.0006, n 5), and SB (p 0.009, n 5). Average levels of GAGs are
shown in ng/mg of tissue with S.E. *, p 0.05; **, p 0.01; ***, p 0.001.
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The presence of excess HA seems to be compatible with nor-
mal embryogenesis, as the TKOmice appeared normal at birth.
This is in contrast to the hyaluronan synthase-2 knock-out
mice, which die at embryonic day 9.5 due to a failure to synthe-
size HA (37). It seems likely that the presence of excess HA
allows for normal development, and the failure to degrade HA
does not lead to detectable symptoms until the postnatal
period.
Along with HA accumulation, TKO mice also displayed
global accumulation of non-sulfated chondroitin. This chon-
droitin is a GAG very similar to HA but is not a normal com-
ponent of mouse tissues. This suggests that the chondroitin
found in the TKO tissues may be derived from intermediates of
chondroitin sulfatemetabolism that have already been acted on
by sulfatases. The presence of chondroitin in TKO (but not
DKO or HYAL1-deficient) tissues provides evidence that a
combined loss of HYAL1 and -hexosaminidase activities
affected the degradation pathways of multiple GAGs.
Previous studies have shown that likeHA, sulfated chondroi-
tin degradation occurs in the lysosome (39, 40) and that the
same cell surface receptors for endocytosis are possibly shared
(41, 42). Once within the lysosome, the contribution of each
lysosomal enzyme to the degradation of sulfated chondroitin is
unknown, but both a hyaluronidase (43) and an exoglycosidase
(44) have been suggested to have a role. Recently, human
HYAL4, thought to be a chondroitinase, was further character-
ized and confirmed to be a chondroitin sulfate-specific hydro-
lyase with little to no activity toward HA and dermatan sulfate
(45). However, HYAL4 displays tissue-specific expression
primarily in the placenta and skeletal muscle (46), suggesting
that other enzymes also play a role in chondroitin sulfate
degradation.
Sulfated derivatives of chondroitinwere found to accumulate
in a tissue-specific manner in mice lacking just -hexosamini-
dase activity and inmice with the combined loss of HYAL1 and
-hexosaminidase. However, no accumulation was found in
mice lacking onlyHYAL1 activity.-Hexosaminidase-deficient
mice accumulated several sulfated types of chondroitin, includ-
ing that of dermatan sulfate, providing evidence that -hexo-
saminidase has the ability to cleave multiple types of sulfated
chondroitin in vivo. Furthermore, the accumulation of chon-
droitin sulfate in the brain and the additional accumulation in
the liver after the combined loss of HYAL1 and -hexosamini-
dase demonstrate, for the first time in vivo, that sulfated chon-
droitin derivatives are also substrates of HYAL1. Accumulation
in the brain and liver implies that HYAL1 and -hexosamini-
dase compensate for one another in a tissue-specific manner.
The lack of chondroitin sulfate accumulation in other tissues
such as the skin after the combined loss of HYAL1 and -hexo-
saminidase implies that other enzymes are present, HYAL4
being a possible candidate.
In our study, a difference in the detection of HA when using
HABP as opposed to FACEwas apparent. Some possible expla-
nations for this discrepancy include the effects of fixation and
the specificity of HABP. Fixation of tissue can cause extraction
of GAGs, resulting in a decreased signal. Frozen tissue was used
for FACE analyses; and thus, extraction of GAGs was not a
factor. It has also been shown that a decasaccharide is the small-
est HA fragment able to strongly bind with the HABP (47, 48).
Thus, it is possible that the accumulating HA in the paraffin
tissue sections was not recognized because the size of intracel-
lular HA may have been too small for detection. Therefore, we
consider FACE as a more reliable assay for the detection and
quantification of HA. Furthermore, the limitations of HABP
need to be taken into account when this technique is used.
To conclude, this study describes extensive global accumu-
lation ofHA inmice thatweremodified to have a combined loss
of HYAL1 and -hexosaminidase activities. The lack of broad
HA accumulation inmice deficient in either a hyaluronidase or
an exoglycosidase suggests that there is a functional redun-
dancy among the lysosomal HA-degrading enzymes, HYAL1,
and -hexosaminidase. Moreover, the loss of both HYAL1 and
-hexosaminidase activities creates an obstacle in overall GAG
degradation as noted by the broad accumulation of chondroitin
in the TKOmice, thus providing further evidence that HA and
other GAGs share a common degradation route. Furthermore,
for the first time in vivo, both HYAL1 and -hexosaminidase
were shown to degrade multiple types of chondroitin sulfate
and to share a tissue-specific functional redundancy. Future
studies combining the loss of other hyaluronidase-like enzymes
will be required to determine whether and to what degree other
hyaluronidases and exoglycosidases contribute to the degrada-
tion of HA and other GAGs.
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